Latest Us Market News

Vitasora Health Limited reported robust patient program growth and secured new US partnerships, driving revenue above A$1 million for the quarter. A recent A$11 million capital raise positions the company for continued expansion and cash-flow breakeven by late 2026.

Terra Critical Minerals (ASX, T92) broadens its critical minerals portfolio with new US initiatives and promising exploration in New South Wales and Canada. The company also pursues a US OTC listing to tap North American capital.

Pure Hydrogen Corporation reported strong commercial momentum in the September 2025 quarter, securing multiple hydrogen vehicle orders across Australia and the US, expanding international distribution, and raising fresh capital to fuel growth.

International Graphite Limited has made significant strides in its global graphite strategy, signing a German joint venture and securing $3 million in US institutional funding to support its expanding mine-to-market operations.

Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.

Cobram Estate Olives Limited has reported a record-breaking FY2025, driven by strong sales growth in Australia and the USA, alongside a $178 million equity raise to accelerate its Californian olive grove expansion.

West Cobar Metals reports significant progress across its WA and NSW projects, with promising assay results for rare earths and base metals, alongside strategic engagement in the US market and a recent $1.25 million capital raise.

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

Jindalee Lithium is progressing its McDermitt Lithium Project with a proposed US SPAC listing, government backing, and an $8 million capital raise, positioning it as a key player in the US critical minerals landscape.

Pinnacle Minerals has raised $2.2 million to fund its strategic expansion into the US critical minerals sector, acquiring eight new projects and commencing exploration activities in Idaho and Washington State.